Answers are grounded in this paper and cite their sources.
Non-small cell lung cancer (NSCLC) has a persistently high incidence and mortality rate, and brain metastasis is one of the common complications with a poor prognosis. At present, cranial radiotherapy is a key treatment for controlling the progression of brain metastases, but its efficacy remains limited. Anlotinib is a multitarget tyrosine kinase inhibitor that can significantly prolong the survival of patients with advanced NSCLC. Clinical studies have found that anlotinib combined with cranial radiotherapy can delay the progression of brain metastases with good safety. This review mainly discusses the mechanisms and clinical efficacy of this combination strategy in NSCLC with brain metastases, aiming to provide a new and effective therapeutic option for these patients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: